WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ:KYMR) on behalf of the company's shareholders. The investigation seeks to
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:KYMR) breached their fiduciary
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621
WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:KYMR) breached their fiduciary
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:KYMR) breached their
NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ:KYMR) on behalf of the company's shareholders. The investigation seeks to
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027,
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be
